2m 2m 2m 2m 2m 2m 2m
ALTO NEURO (ANRO)
NYSE
$18.97+$0.26 (+1.39%)
Price as of Jun 03, 2026 7:28 PM EDT- $704.3MMarket Cap
- 611.41%1-Year Change
- BiotechnologyIndustry
ALTO NEURO (ANRO)
$18.97+$0.26 (+1.39%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -45.6M -2.93% | -47.0M N/A | |
Depreciation and Amortization Expense | 661,000 +31.67% | 502,000 N/A | |
Total Operating Expenses | 66.4M -3.27% | 68.6M N/A | |
Operating Profit | -66.4M -3.27% | -68.6M N/A | |
Interest Income | 6.6M -25.40% | 8.9M N/A | |
Interest Expense | -2.5M +78.57% | -1.4M N/A | |
Interest Income and Expense and Net | 4.1M -44.93% | 7.5M N/A | |
Total Nonoperating Income and Expense | 3.1M -56.46% | 7.2M N/A | |
Income before Taxes | -66.4M -3.27% | -68.6M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -63.2M +2.94% | -61.4M N/A | |
Net Income from Continuing Operations Applicable to Common | -63.2M +2.94% | -61.4M N/A | |
Basic EPS and Net Income | -2.19 -12.40% | -2.50 N/A | |
Diluted EPS and Net Income | -2.19 -12.40% | -2.50 N/A | |
Basic Weighted Average Shares | 28.9M +17.28% | 24.6M N/A | |
Diluted Weighted Average Shares | 28.9M +17.28% | 24.6M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 176.5M +4.91% | 168.2M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 176.5M +4.91% | 168.2M N/A | |
Total Current Assets | 177.7M +4.95% | 169.3M N/A | |
Accumulated Depreciation | 1.5M +51.99% | 1.0M N/A | |
Property and Plant and Equipment and Net | 1.9M -29.78% | 2.7M N/A | |
Total Long-Term Assets | 338,000 +8,350.00% | 4,000 N/A | |
Total Assets | 184.7M +4.03% | 177.5M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 585,000 N/A | 0 N/A | |
Total Current Liabilities | 11.3M +13.16% | 10.0M N/A | |
Total Long-Term Debt | 18.4M +59.19% | 11.6M N/A | |
Total Long-Term Liabilities | 20.0M +35.38% | 14.8M N/A | |
Total Liabilities | 33.5M +28.62% | 26.1M N/A | |
Retained Earnings | -201.6M +45.69% | -138.4M N/A | |
Total Stockholders Equity | 151.1M -0.21% | 151.5M N/A | |
Total Shares Outstanding | 31.9M +18.29% | 27.0M N/A | |
Cash Flow | |||
Cash from Operating Activities | -51.8M +9.16% | -47.4M N/A | |
Capital Expenditures | 24,000 -98.84% | 2.1M N/A | |
Cash from Investing Activities | -24,000 -98.84% | -2.1M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 60.1M -55.72% | 135.7M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -34.92% N/A | N/A N/A | |
Return on Equity | -41.80% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 15.69 N/A | N/A N/A | |
Cash Ratio | 15.58 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.13 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.10 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow